{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T01:34:36Z","timestamp":1790818476395,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1097\/hjh.0000000000000071","type":"journal-article","created":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T17:21:02Z","timestamp":1388424062000},"page":"681-692","source":"Crossref","is-referenced-by-count":24,"title":["Cost-effectiveness of Barostim therapy for the treatment of resistant hypertension in European settings"],"prefix":"10.1097","volume":"32","author":[{"given":"Oleg","family":"Borisenko","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Beige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric G.","family":"Lovett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta C.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Bjessmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-30-20210208","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jama.1996.03530440051036","article-title":"Blood pressure as a cardiovascular risk factor: prevention and treatment.","volume":"275","author":"Kannel","year":"1996","journal-title":"JAMA"},{"key":"R2-30-20210208","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1161\/01.HYP.0000103630.72812.10","article-title":"Hypertension treatment and control in Five European countries, Canada, and the United States.","volume":"43","author":"Wolf-Maier","year":"2004","journal-title":"Hypertension"},{"key":"R3-30-20210208","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s11906-011-0226-7","article-title":"Resistant hypertension: concepts and approach to management.","volume":"13","author":"Sander","year":"2011","journal-title":"Curr Hypertens Rep"},{"key":"R4-30-20210208","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). ESHESC Guidelines for the management of arterial hypertension.","volume":"31","author":"Mancia","year":"2013","journal-title":"J Hypertens"},{"key":"R6-30-20210208","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0195-668X(03)00114-3","article-title":"Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project.","volume":"24","author":"Conroy","year":"2003","journal-title":"Eur Heart J"},{"key":"R7-30-20210208","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0002-8703(91)90861-B","article-title":"Cardiovascular disease risk profiles.","volume":"121","author":"Anderson","year":"1991","journal-title":"Am Heart J"},{"key":"R8-30-20210208","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1161\/01.STR.25.1.40","article-title":"Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study.","volume":"25","author":"DAgostino","year":"1994","journal-title":"Stroke"},{"key":"R9-30-20210208","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/archinte.159.11.1197","article-title":"Profile for estimating risk of heart failure.","volume":"159","author":"Kannel","year":"1999","journal-title":"Arch Intern Med"},{"key":"R10-30-20210208","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","article-title":"Probability of stroke: a risk profile from the Framingham study.","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"R11-30-20210208","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archinte.165.8.923","article-title":"Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease.","volume":"165","author":"Hsu","year":"2005","journal-title":"Arch Intern Med"},{"key":"R14-30-20210208","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jacc.2011.06.008","article-title":"Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled Rheos Pivotal trial.","volume":"58","author":"Bisognano","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R15-30-20210208","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(10)62039-9","article-title":"Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 trial): a randomised controlled trial.","volume":"376","author":"Esler","year":"2010","journal-title":"Lancet"},{"key":"R16-30-20210208","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1097\/01.hjh.0000379526.21089.39","article-title":"Sustained blood pressure reduction by Baroreflex activation therapy with a chronically implanted system: 4-year data of Rheos Debut-HT study in patients with resistant hypertension.","volume":"28","author":"Kroon","year":"2010","journal-title":"J Hypertens"},{"issue":"suppl 4","key":"R17-30-20210208","first-page":"S421","article-title":"Sustained blood pressure reduction by baroreflex hypertension therapy with a chronically implanted system: 3-year data from the Rheos DEBuT study in patients with resistant hypertension.","volume":"27","author":"Scheffers","year":"2009","journal-title":"J Hypertens"},{"key":"R18-30-20210208","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1016\/j.jacc.2010.03.089","article-title":"Novel baroreflex activation therapy in resistant hypertension: results of a European multicenter feasibility study.","volume":"56","author":"Scheffers","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R19-30-20210208","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jash.2012.04.004","article-title":"Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial.","volume":"6","author":"Hoppe","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"R20-30-20210208","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2796.1998.00394.x","article-title":"Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Goteborg, Sweden.","volume":"244","author":"Rosengren","year":"1998","journal-title":"J Intern Med"},{"key":"R21-30-20210208","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1097\/00004872-200106000-00021","article-title":"Effects of individual risk factors on the incidence of cardiovascular events in the treated hypertensive patients of the Hypertension Optimal Treatment Study. HOT Study Group.","volume":"19","author":"Zanchetti","year":"2001","journal-title":"J Hypertens"},{"key":"R22-30-20210208","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1001\/jama.2009.1178","article-title":"Reduction in acute myocardial infarction mortality in the United States: risk-standardized mortality rates from 1995-2006.","volume":"302","author":"Krumholz","year":"2009","journal-title":"JAMA"},{"key":"R23-30-20210208","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1161\/01.STR.24.6.796","article-title":"Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.","volume":"24","author":"Dennis","year":"1993","journal-title":"Stroke"},{"key":"R24-30-20210208","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1001\/jama.2011.1650","article-title":"Level of systolic blood pressure within the normal range and risk of recurrent stroke.","volume":"306","author":"Ovbiagele","year":"2011","journal-title":"JAMA"},{"key":"R25-30-20210208","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1046\/j.1523-1755.2003.00101.x","article-title":"Elevated risk of stroke among patients with end-stage renal disease.","volume":"64","author":"Seliger","year":"2003","journal-title":"Kidney Int"},{"key":"R27-30-20210208","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.cardfail.2007.01.009","article-title":"The incidence of ischemic stroke in chronic heart failure: a meta-analysis.","volume":"13","author":"Witt","year":"2007","journal-title":"J Cardiac Fail"},{"key":"R28-30-20210208","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/01.CIR.0000054165.93055.42","article-title":"Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.","volume":"107","author":"Arnold","year":"2003","journal-title":"Circulation"},{"key":"R29-30-20210208","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1161\/CIRCULATIONAHA.108.784215","article-title":"Long-term trends in the incidence of heart failure after myocardial infarction.","volume":"118","author":"Velagaleti","year":"2008","journal-title":"Circulation"},{"key":"R30-30-20210208","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1681\/ASN.2006091048","article-title":"Effect of age, gender, and diabetes on excess death in end-stage renal failure.","volume":"18","author":"Villar","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"R31-30-20210208","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/eurheartj\/ehi696","article-title":"Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis.","volume":"27","author":"de Silva","year":"2006","journal-title":"Eur Heart J"},{"key":"R32-30-20210208","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1681\/ASN.V115917","article-title":"Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada.","volume":"11","author":"Rabbat","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"R34-30-20210208","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1007\/s10389-005-0112-3","article-title":"Cost of atherothrombotic diseasesmyocardial infarction, ischaemic stroke and peripheral arterial occlusive diseasein Germany.","volume":"13","author":"Bruggenjurgen","year":"2005","journal-title":"J Public Health"},{"key":"R35-30-20210208","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1524-4733.2004.72314.x","article-title":"Resource utilization and costs of stroke unit care in Germany.","volume":"7","author":"Dodel","year":"2004","journal-title":"Value Health"},{"key":"R36-30-20210208","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1161\/01.STR.0000217450.21310.90","article-title":"Lifetime cost of ischemic stroke in Germany: results and national projections from a population-based stroke registry - the Erlangen Stroke Project.","volume":"37","author":"Kolominsky-Rabas","year":"2006","journal-title":"Stroke"},{"key":"R37-30-20210208","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1093\/eurheartj\/ehl016","article-title":"Dialysis: a regional population-based analysis. Nephrology Assessment of Reduction in Mortality and Morbidity (CHARM) programme.","volume":"27","author":"McMurray","year":"2006","journal-title":"Eur Heart J"},{"key":"R38-30-20210208","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1093\/ndt\/gfp672","article-title":"Costs of dialysis: a regional population-based analysis.","volume":"25","author":"Icks","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"R39-30-20210208","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1097\/01.TP.0000121763.44137.FA","article-title":"Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities, and complications.","volume":"77","author":"Hagenmeyer","year":"2004","journal-title":"Transplantation"},{"key":"R43-30-20210208","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.ejheart.2005.01.012","article-title":"The impact of chronic heart failure on health-related quality of life data acquired in the baseline phase of the CARE-HF study.","volume":"7","author":"Calvert","year":"2005","journal-title":"Eur J Heart Fail"},{"key":"R44-30-20210208","first-page":"487","article-title":"Are the modified simple questions a valid and reliable measure of health related quality of life after stroke J Neurol Neurosurg P","volume":"69","author":"Dorman","year":"2000","journal-title":"sychiatry"},{"key":"R45-30-20210208","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1161\/01.STR.0000196990.69412.fb","article-title":"Long-term outcome after stroke.","volume":"37","author":"Haacke","year":"2006","journal-title":"Stroke"},{"key":"R46-30-20210208","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1185\/030079905X65277","article-title":"Characterisation and comparison of health-related quality of life for patients with renal failure.","volume":"21","author":"Lee","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R47-30-20210208","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1001\/jama.288.15.1851","article-title":"Cost and cost-effectiveness of an early invasive vs conservative strategy for the treatment of unstable angina and non-ST-segment elevation myocardial infarction.","volume":"288","author":"Mahoney","year":"2002","journal-title":"JAMA"},{"key":"R48-30-20210208","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1524-6175.2002.00970.x","article-title":"The quality of life of patients with hypertension.","volume":"4","author":"Stein","year":"2002","journal-title":"J Clin Hypertens"},{"key":"R49-30-20210208","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1177\/0272989X11401031","article-title":"Catalogue of EQ-5D scores for the United Kingdom.","volume":"31","author":"Sullivan","year":"2011","journal-title":"Med Decis Making"},{"key":"R50-30-20210208","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00103-012-1490-7","article-title":"The Heinz Nixdorf Recall study.","volume":"55","author":"Erbel","year":"2012","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"R51-30-20210208","first-page":"518","article-title":"Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge Value H","volume":"7","author":"Eichler","year":"2004","journal-title":"ealth"},{"key":"R54-30-20210208","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(05)67185-1","article-title":"Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.","volume":"366","author":"Dahlof","year":"2005","journal-title":"Lancet"},{"key":"R55-30-20210208","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/00004872-200106000-00020","article-title":"Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial ASCOT investigators.","volume":"19","author":"Sever","year":"2001","journal-title":"J Hypertens"},{"key":"R56-30-20210208","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/j.1751-7176.2009.00163.x","article-title":"Cost-effectiveness of treating resistant hypertension with an implantable carotid body stimulator.","volume":"11","author":"Young","year":"2009","journal-title":"J Clin Hypertens"},{"key":"R57-30-20210208","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/j.jacc.2012.07.029","article-title":"Cost-effectiveness and clinical effectiveness of catheter-based renal denervation for resistant hypertension.","volume":"60","author":"Geisler","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R58-30-20210208","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jval.2012.06.014","article-title":"State-Transition Modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3.","volume":"15","author":"Siebert","year":"2012","journal-title":"Value Health"},{"key":"R59-30-20210208","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jash.2012.01.003","article-title":"Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal trial.","volume":"6","author":"Bakris","year":"2012","journal-title":"J Am Soc Hypertens"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/HJH.0000000000000071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T02:05:53Z","timestamp":1647828353000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201403000-00030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0000000000000071","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}